Rare Cases Of COVID Returning Pose Questions For Pfizer Pill
Companies, agencies, institutions, etc
AP
Pfizer
Paxlovid’s
the Food and Drug Administration
Charness
FDA
Johns Hopkins University
Pekosz
University of Minnesota
@AP_FDAwriter___The Associated Press Health and Science Department
the Howard Hughes Medical Institute’s Department of Science Education
People
Michael Charness
Andy Pekosz
David Boulware
’d
Matthew Perrone
Groups
COVID-19
Americans
Physical locations
No matching tags
Places
No matching tags
Locations
WASHINGTON
U.S.
Paxlovid
Boston
Pfizer
Boulware
Events
No matching tags
Summary
The U.S. government has spent more than $10 billion to purchase enough pills to treat 20 million people.But experts say there is still much to be learned about the drug, which was authorized in December for adults at high risk of severe COVID-19 based on a study in which 1,000 adults received the medication.WHY DO SOME PATIENTS SEEM TO RELAPSE?Doctors have started reporting rare cases of patients whose symptoms return several days after completing Paxlovid’s five-day regimen of pills.
As said here by AP